Dr. Aditi Kumar on Aggressive Multimodal Therapy in Anaplastic Thyroid Cancer

Aditi Kumar, MD
Published: Wednesday, Oct 21, 2015



Aditi Kumar, MD, endocrinology fellow, University of Mississippi, discusses aggressive multimodal therapy in anaplastic thyroid cancer.

A study conducted at the Mayo Clinic, where Kumar was previously a fellow, looked at 29 patients with stage IV, A, B and C anaplastic thyroid cancer, a rare form of thyroid cancer with poor outcomes. Often, patients are not treated at this stage, as options are limited and toxicities from treatments can be high, says Kumar.

The patients in this trial were treated with surgery if it was possible, intensity modulated radiation therapy, and chemotherapy. This combination of treatment resulted in 22.4 months median overall survival (OS), compared to 5 months median OS with standard of care. One-year survival was 61%.

Toxicities with this aggressive treatment were significant, so patients should be included in discussions concerning treatment requirements and risks, says Kumar.

<<< View more from the 2015 International Thyroid Congress



Aditi Kumar, MD, endocrinology fellow, University of Mississippi, discusses aggressive multimodal therapy in anaplastic thyroid cancer.

A study conducted at the Mayo Clinic, where Kumar was previously a fellow, looked at 29 patients with stage IV, A, B and C anaplastic thyroid cancer, a rare form of thyroid cancer with poor outcomes. Often, patients are not treated at this stage, as options are limited and toxicities from treatments can be high, says Kumar.

The patients in this trial were treated with surgery if it was possible, intensity modulated radiation therapy, and chemotherapy. This combination of treatment resulted in 22.4 months median overall survival (OS), compared to 5 months median OS with standard of care. One-year survival was 61%.

Toxicities with this aggressive treatment were significant, so patients should be included in discussions concerning treatment requirements and risks, says Kumar.

<<< View more from the 2015 International Thyroid Congress


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Key Questions for the Use of Immunotherapy Throughout the Disease Continuum for NSCLC in an Era of Rapid DevelopmentSep 29, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing GlioblastomaSep 29, 20182.0
Publication Bottom Border
Border Publication
x